- NPS Pharmaceuticals (NASDAQ:NPSP +8.1%) Q3 results: Revenues: $57.2M (+45.9%); COGS: $3.2M (+190.9%); R&D Expense: $24.5M (+30.3%); SG&A: $28.1M (+59.7%); Operating Income: $1.4M (-22.2%); Net Loss: ($2.1M) (-90.9%); Loss Per Share: ($0.02) (-100.0%); Quick Assets: $169.3M (-6.2%).
- 2014 Guidance: Sales: $100M from $100M - 110M; operating expenses: $185M - 195M from $180M - 200M.